Latest Conference Articles

Faith Mutale, CRNP, discusses the paradigm shift needed in oncology to address clinical trial enrollment hesitancy among African American patients with lung cancer.

Sarah Donahue, MPH, NP, AOCNP, explains the trial design of the pivotal DESTINY-Breast04 trial and discusses how the promising performance of trastuzumab deruxtecan might impact patients with unresectable or metastatic HER2-low breast cancer.

Beth Sandy, MSN, CRNP, discusses some of the challenges that may be associated with molecular testing, and how oncology nurses can help play a role in ensuring that the reports are received.

In the modern era, the number of patients with diffuse large B-cell lymphoma who will derive benefit from autologous stem cell transplantation is small, according to Jeremy S. Abramson, MD, MMSc.

Kelley A. Rone, DNP, RN, AGNP-c, discusses the advantages associated with immunotherapy in the treatment of patients with gastrointestinal cancers.

An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.

Lidia Schapira, MD, FASCO, discusses the importance of rigorous baseline measurement in improving the assessment and management of distressful cancer symptoms.

An expert with the Washington University School of Medicine in St Louis outlines the benefit of rituximab, and other maintenance therapies, for patients with mantel cell lymphoma who are in remission.

Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

A quality time without symptoms of toxicities analysis of the pivotal ZUMA-7 trial found that patients with relapsed or refractory large B-cell lymphoma experienced longer time without toxicity with axicabtagene ciloleucel than with standard of care.

A combined analysis of 3 real-world studies assessing the use of ixazomib/lenalidomide/dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma found the patient outcomes to be consistent with original phase 3 findings.

Patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, achieved superior progression-free survival with zanubrutinib vs a combination of bendamustine plus rituximab.

Because immune-related adverse events can be hard to diagnose, patient education and clear avenues of communication with an oncology care team are critical, according to investigators at the 2022 Pan Pacific Lymphoma Conference.

The ideal model for promoting effective shared decision-making involves tailored caregiver education, adequate time before treatment, and use of multidisciplinary support.

Brexucabtagene autoleucel, a CAR T-cell therapy approved in 2021 for relapsed or refractory B-cell acute lymphoblastic leukemia, showed efficacious results and promising safety data at 2-year follow-up.

Gretchen McNally PhD, ANP-BC, AOCN, spotlights the value that naloxone training for oncology nurses and providers could have for patients who are at a high-risk of overdose.

Arndt Vogel, MD, PhD, discusses a post-hoc analysis of the phase 3 HIMALAYA trial which found tremelimumab plus durvalumab to be superior to sorafenib in improving overall survival.

Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.

Patients receiving bevacizumab plus olaparib to treat newly diagnosed ovarian cancer experienced significantly longer time without signs of toxicity compared with placebo.

Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.

An expert of gastrointestinal oncology with the Henry Ford Cancer Institute discusses the developing presence of targeted treatments in the pancreatic cancer treatment paradigm.

Ilene Galinsky, BSN, MSN, ANP-C, underscores effective symptom management strategies when prescribing venetoclax to patients with acute myeloid leukemia.

Dexamethasone sparing in cisplatin-based chemotherapy did not impair global health status, although it did worsen nausea and appetite loss.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, presents a case study of a patient receiving chemotherapy for osteosarcoma who begins experiencing shortness of breath.

Nurse navigators may play a key role in mitigating toxicities from chemotherapy and perform geriatric assessments for patients treated at hematology/oncology clinics.

Ilene Galinsky, BSN, MSN, ANP-C, discusses the evolution of targeted therapy in acute myeloid leukemia treatment, and how venetoclax plays into the treatment paradigm.

Investigators have identified that zanubrutinib may improve the subpar health-related quality of life for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.

Darcy Burbage, DNP, RN, AOCN, CBCN, discusses the top takeaways from the 2022 ASCO Annual Meeting for oncology nurses.

An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.

Data from the CheckMate 648 trial informed the FDA’s recent approval of 2 nivolumab combinations for esophageal squamous cell carcinoma. A 1-year follow-up analysis highlighted key safety and time-to-event data surrounding immune-related toxicities.